This engaging live webinar will convene a panel of thoracic oncologists, researchers, and patient advocates to consider current controversies in EGFRm NSCLC arising from the emergence of rapidly evolving science and social media. COVID-19 has added a layer of complexity to decision-making in 2020. Has it also changed what we consider as standards of clinical practice?
Much like the tumor board model, there is a complex continuum matrix between researchers who study new treatments for NSCLC and run clinical trials, clinicians involved in applying the information in community settings, and patients who receive the treatments. Given the fast-paced nature of advances in this space, communication of accurate information is critical. Dissemination via social media can accelerate communications, but also creates opportunities for misinformation and confusion.
We envision a lively session of networking with a diverse panel of top experts, young investigators, and patient advocates. We will debate common “myths” related to testing, treatment selection, resistance, and clinical trials within the context of EGFRm NSCLC. Our panel will explore these common myths to determine factual basis and erroneous misconceptions to provide the best level of evidence for practical application to patient care.
This activity has been planned for clinical oncologists and oncology specialty pharmacists, nurses, and physician assistants who are managing patients with NSCLC. Lung cancer patients are also invited to view the presentation.
At the conclusion of this live internet, application-based activity, participants will apply in practice the skills and/or knowledge to:
- Consider guideline-directed recommendations for tissue and liquid biopsy testing for biomarkers in non-small cell lung cancer (NSCLC).
- Explain existing evidence for first-line treatment options in newly diagnosed EGFRm NSCLC.
- Debate clinical controversies in sequencing EGFR TKIs with or without adjuvant chemotherapy, immunotherapy, and radiotherapy
- Explore best practices for treatment post development of osimertinib resistance.
- Examine perspectives of others on the lung cancer team and in the lung cancer community and consider ways to improve communication and accuracy of information that is shared.